MAR-arkiv - Page 3 of 5 - Isofol Medical

Isofol Medical AB (publ) will not reach 300 PFS events in the AGENT study with current censoring rules based on FDA decision

GOTHENBURG, Sweden, December 3, 2021 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL), announced today that the U.S. Food and […]

Isofol Medical AB (publ) receives FDA Fast Track Designation for arfolitixorin in advanced colorectal cancer (mCRC)

GOTHENBURG, Sweden, November 23, 2021 – Isofol Medical AB (http://isofol.se/en/) (publ) (Nasdaq Stockholm: ISOFOL), announced today that the U.S. Food and

Isofol raises SEK 500 million in oversubscribed rights issue and exercised over-allotment option

GOTHENBURG, Sweden, June 14, 2021 – Isofol Medical AB (publ) (Nasdaq First North Premier Growth Market: ISOFOL) (“Isofol” or the

Isofol’s Board of Directors resolves on a fully guaranteed preferential rights issue of approximately SEK 400 million

GOTHENBURG, Sweden, May 18, 2021 – Isofol Medical AB’s (publ), (Nasdaq First North Premier Growth Market: ISOFOL), (“Isofol or the

Isofol announces its intention to carry out a fully guaranteed preferential rights issue of approximately SEK 400 million and a potential over-allotment option of up to approximately SEK 100 million

GOTHENBURG, Sweden, April 28, 2021 – Isofol Medical AB (publ), (Nasdaq First North Premier Growth Market: ISOFOL), hereby announces that

Isofol receives recommendation from iDSMB to complete the global Phase III AGENT study for market registration as planned with 440 patients

GOTHENBURG, Sweden, March 19, 2021 – Isofol Medical AB (publ) (“Isofol”), (Nasdaq First North Premier Growth Market: ISOFOL) announces that

MAR

Isofol Medical AB (publ) will not reach 300 PFS events in the AGENT study with current censoring rules based on FDA decision

Isofol Medical AB (publ) receives FDA Fast Track Designation for arfolitixorin in advanced colorectal cancer (mCRC)

Isofol raises SEK 500 million in oversubscribed rights issue and exercised over-allotment option

Isofol’s Board of Directors resolves on a fully guaranteed preferential rights issue of approximately SEK 400 million

Isofol announces its intention to carry out a fully guaranteed preferential rights issue of approximately SEK 400 million and a potential over-allotment option of up to approximately SEK 100 million

Isofol receives recommendation from iDSMB to complete the global Phase III AGENT study for market registration as planned with 440 patients

Isofol announces licensing agreement for Paladin Labs Inc. to commercialize arfolitixorin in Canada

Isofol enters licensing agreement with Solasia to develop and commercialize arfolitixorin in Japan

Isofol’s rights issue oversubscribed

Isofol’s Board of Directors resolve on a fully guaranteed preferential rights issue of approximately SEK 150 million